دورية أكاديمية
أعرض في EDS

Putative Clinical Potential of ERBB2 Amplification Assessment by ddPCR in FFPE-DNA and cfDNA of Gastroesophageal Adenocarcinoma Patients.

التفاصيل البيبلوغرافية
العنوان: Putative Clinical Potential of ERBB2 Amplification Assessment by ddPCR in FFPE-DNA and cfDNA of Gastroesophageal Adenocarcinoma Patients.
المؤلفون: Boldrin E; Immunology and Molecular Oncology, Veneto Institute of Oncology IOV-IRCCS, Via Gattamelata 64, 35128 Padova, Italy., Mazza M; Surgical Oncology of the Esophagus and Digestive Tract Unit, Veneto Institute of Oncology IOV-IRCCS, Via dei Carpani 16, 31033 Castelfranco Veneto, Italy., Piano MA; Immunology and Molecular Oncology, Veneto Institute of Oncology IOV-IRCCS, Via Gattamelata 64, 35128 Padova, Italy., Alfieri R; Surgical Oncology of the Esophagus and Digestive Tract Unit, Veneto Institute of Oncology IOV-IRCCS, Via dei Carpani 16, 31033 Castelfranco Veneto, Italy., Montagner IM; Pathology Unit, Veneto Institute of Oncology IOV-IRCCS, Via dei Carpani 16, 31033 Castelfranco Veneto, Italy., Magni G; Clinical Research Unit, Veneto Institute of Oncology IOV-IRCCS, Via Gattamelata 64, 35128 Padova, Italy., Scaini MC; Immunology and Molecular Oncology, Veneto Institute of Oncology IOV-IRCCS, Via Gattamelata 64, 35128 Padova, Italy., Vassallo L; Pathology Unit, Veneto Institute of Oncology IOV-IRCCS, Via dei Carpani 16, 31033 Castelfranco Veneto, Italy., Rosato A; Immunology and Molecular Oncology, Veneto Institute of Oncology IOV-IRCCS, Via Gattamelata 64, 35128 Padova, Italy.; Oncology and Immunology Section, Department of Surgery Oncology and Gastroenterology, University of Padova, Via Gattamelata 64, 35128 Padova, Italy., Pilati P; Surgical Oncology of the Esophagus and Digestive Tract Unit, Veneto Institute of Oncology IOV-IRCCS, Via dei Carpani 16, 31033 Castelfranco Veneto, Italy., Scapinello A; Pathology Unit, Veneto Institute of Oncology IOV-IRCCS, Via dei Carpani 16, 31033 Castelfranco Veneto, Italy., Curtarello M; Immunology and Molecular Oncology, Veneto Institute of Oncology IOV-IRCCS, Via Gattamelata 64, 35128 Padova, Italy.
المصدر: Cancers [Cancers (Basel)] 2022 Apr 27; Vol. 14 (9). Date of Electronic Publication: 2022 Apr 27.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Anti-HER2 monoclonal antibody trastuzumab improves the survival of those patients with advanced gastroesophageal adenocarcinoma (GEA) exhibiting HER2/ ERBB2 overexpression/amplification. The current gold standard methods used to diagnose the HER2 status in GEA are immunohistochemistry (IHC) and silver or fluorescence in situ hybridization (SISH or FISH). However, they do not permit spatial and temporal tumor monitoring, nor do they overcome intra-cancer heterogeneity. Droplet digital PCR (ddPCR) was used to implement the assessment of HER2 status in formalin-fixed paraffin-embedded (FFPE) tumor DNA from a retrospective cohort (86 patients) and in cell-free DNA (cfDNA) samples from a prospective cohort (28 patients). In comparison to IHC/SISH, ddPCR assay revealed ERBB2 amplification in a larger patient fraction, including HER2 2+ and 0-1+ of the retrospective cohort (45.3% vs. 15.1%). In addition, a considerable number of HER2 2+ and 0-1+ prospective patients who were negative in FFPE by both IHC/SISH and ddPCR, showed ERBB2 amplification in the cfDNA collected just before surgery. cfDNA analysis in a few longitudinal cases revealed an increasing ERBB2 trend at progression. In conclusion, ddPCR in liquid biopsy may improve the detection rate of HER2 positive patients, preventing those patients who could benefit from targeted therapy from being incorrectly excluded.
References: Br J Cancer. 2021 Jul;125(1):94-100. (PMID: 33953347)
Arch Pathol Lab Med. 2016 Dec;140(12):1345-1363. (PMID: 27841667)
Sci Rep. 2020 Mar 6;10(1):4177. (PMID: 32144300)
Ann Oncol. 2005 Feb;16(2):273-8. (PMID: 15668283)
Future Oncol. 2021 Nov;17(31):4101-4114. (PMID: 34463133)
JCO Precis Oncol. 2022 Jan;6:e2100330. (PMID: 35050711)
Ann Oncol. 2021 Feb;32(2):229-239. (PMID: 33232761)
Clin Cancer Res. 2017 Aug 1;23(15):4441-4449. (PMID: 28747339)
Lancet. 2010 Aug 28;376(9742):687-97. (PMID: 20728210)
J Clin Oncol. 2016 Feb 10;34(5):443-51. (PMID: 26628478)
Cells. 2021 Jul 28;10(8):. (PMID: 34440680)
Lancet Oncol. 2017 May;18(5):640-653. (PMID: 28343975)
World J Gastrointest Oncol. 2022 Mar 15;14(3):628-645. (PMID: 35321271)
Clin Cancer Res. 2018 Dec 15;24(24):6248-6256. (PMID: 30348637)
Clin Chem. 2020 Jul 1;66(7):946-957. (PMID: 32516802)
Clin Cancer Res. 2019 Dec 1;25(23):7098-7112. (PMID: 31427281)
Nature. 2017 Jan 12;541(7636):169-175. (PMID: 28052061)
Br J Cancer. 2015 May 12;112(10):1652-5. (PMID: 25897674)
Hum Pathol. 2016 Oct;56:16-21. (PMID: 27342907)
World J Gastrointest Oncol. 2019 Jan 15;11(1):17-27. (PMID: 30984347)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Dig Surg. 2018;35(1):55-63. (PMID: 28441659)
Cell Death Dis. 2019 Sep 20;10(10):697. (PMID: 31541076)
Cancer Discov. 2018 Jan;8(1):37-48. (PMID: 28978556)
J Clin Oncol. 2018 Jul 10;36(20):2105-2122. (PMID: 29846122)
Lancet Oncol. 2018 Oct;19(10):1372-1384. (PMID: 30217672)
Nature. 2014 Sep 11;513(7517):202-9. (PMID: 25079317)
Clin Chem. 2013 Jun;59(6):892-902. (PMID: 23570709)
Am J Gastroenterol. 2017 Aug;112(8):1247-1255. (PMID: 28585555)
Gastric Cancer. 2017 Jan;20(1):126-135. (PMID: 26874951)
Adv Anat Pathol. 2011 Jan;18(1):53-9. (PMID: 21169738)
J Mol Diagn. 2017 Mar;19(2):244-254. (PMID: 28027945)
J Clin Oncol. 2021 May 1;39(13):1468-1478. (PMID: 33764808)
EBioMedicine. 2019 May;43:261-269. (PMID: 31031019)
Dig Dis Sci. 2013 Feb;58(2):397-404. (PMID: 22918687)
Gastroenterol Res Pract. 2019 Jan 31;2019:1750329. (PMID: 30838039)
Gastric Cancer. 2016 Oct;19(4):1066-1079. (PMID: 26581548)
Cancer Discov. 2018 Jan;8(1):49-58. (PMID: 29122777)
Br J Cancer. 2015 Jan 20;112(2):352-6. (PMID: 25490524)
Gut. 2019 Jul;68(7):1152-1161. (PMID: 30269082)
J Clin Oncol. 2014 Jul 1;32(19):2039-49. (PMID: 24868024)
BMC Clin Pathol. 2018 Nov 26;18:12. (PMID: 30498396)
Ann Oncol. 2008 Sep;19(9):1523-9. (PMID: 18441328)
Eur J Cancer. 2018 Jan;88:92-100. (PMID: 29207318)
N Engl J Med. 2020 Jun 18;382(25):2419-2430. (PMID: 32469182)
Lancet. 2019 May 11;393(10184):1948-1957. (PMID: 30982686)
معلومات مُعتمدة: RICERCA CORRENTE 2019-2020 Italian Ministry of Health
فهرسة مساهمة: Keywords: ERBB2; HER2; cell-free DNA (cfDNA); droplet digital PCR (ddPCR); gastroesophageal adenocarcinoma; liquid biopsy
تواريخ الأحداث: Date Created: 20220514 Latest Revision: 20220518
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC9102116
DOI: 10.3390/cancers14092180
PMID: 35565309
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers14092180